| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
iii
|
|
|
|
Contents
|
|
v-vii
|
|
| Reviews |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Biomarkers for small cell lung cancer: Neuroendocrine, epithelial and circulating tumour cells
19 December 2011
Abstract: Small cell lung cancer (SCLC) is characterised by an aggressive clinical course with invariable resistance to chemotherapy despite initially high response rates. There has been little improv...
|
Rachel Stovold,
Fiona Blackhall,
Suzanne Meredith,
JianMei Hou,
Caroline Dive,
Anne White
et al.
|
263-268
|
|
|
|
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
24 January 2012
Abstract: Several randomized trials have recently investigated the role of maintenance treatment for patients with advanced non-small-cell lung cancer (NSCLC) with responding or stable disease after c...
|
Cesare Gridelli,
Filippo de Marinis,
Massimo Di Maio,
Andrea Ardizzoni,
Chandra P. Belani,
Federico Cappuzzo,
Fortunato Ciardiello,
Panagiotis Fidias,
Luis Paz-Ares,
Francesco Perrone,
Robert Pirker,
Luigi De Petris,
Rolf Stahel
et al.
|
269-279
|
|
| Epidemiology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Characteristics of lung cancer in women: Importance of hormonal and growth factors
26 December 2011
Abstract: Based on epidemiological, clinical, and preclinical data, lung carcinogenesis can be distinctive in women, suggesting that women should be treated differently depending on the expression of ...
|
Isabelle Rouquette,
Valérie Lauwers-Cances,
Camille Allera,
Laurent Brouchet,
Julie Milia,
Yvan Nicaise,
Julie Laurent,
Marie-Bernadette Delisle,
Gilles Favre,
Alain Didier,
Julien Mazières
et al.
|
280-285
|
|
|
|
A specific diplotype defined by PPP1R13L rs1970764, CD3EAP rs967591 and ERCC1 rs11615 and lung cancer risk in a Chinese population
15 February 2012
Abstract: Haplotypes defined by multiple loci may be more precise and useful than genotypes in providing risk estimates for particular cancers. Diplotype is defined as a specific combination of two ha...
|
Jiaoyang Yin,
Ulla Vogel,
Yegang Ma,
Huiwen Wang,
Chunhong Wang,
Duohong Liang,
Li Yue,
Jian Ma,
Xinxin Li
et al.
|
286-291
|
|
| Carcinogenesis and molecular biology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
02 December 2011
Abstract: Emergence of acquired resistance is virtually inevitable in patients with a mutation in the epidermal growth factor receptor gene (EGFR) treated with EGFR tyrosine kinase inhibitors (TKIs). ...
|
Kenichi Suda,
Kenji Tomizawa,
Hirotaka Osada,
Yoshihiko Maehara,
Yasushi Yatabe,
Yoshitaka Sekido,
Tetsuya Mitsudomi
et al.
|
292-299
|
|
|
|
Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: In vitro and in vivo studies
19 January 2012
Abstract: Riccardin D is a macrocyclic bisbibenzyl compound extracted from liverwort plant Dumortiera hirsuta. Our previous study showed that riccardin D induced apoptosis of human leukemia cells by t...
|
Xia Xue,
De-Fu Sun,
Cui-Cui Sun,
Hui-Ping Liu,
Bin Yue,
Cui-Rong Zhao,
Hong-Xiang Lou,
Xian-Jun Qu
et al.
|
300-308
|
|
| Diagnosis and pathology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers
08 December 2011
Abstract: EML4-ALK adenocarcinomas constitute a new molecular subgroup of lung tumours that respond very well to crizotinib, an ALK inhibitor. However, the diagnosis of ALK rearrangement in lung cance...
|
Pierre-Alexandre Just,
Aurélie Cazes,
Anne Audebourg,
Anatole Cessot,
Karine Pallier,
Claire Danel,
Marie-Cécile Vacher-Lavenu,
Pierre Laurent-Puig,
Benoît Terris,
Hélène Blons
et al.
|
309-315
|
|
|
|
Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4
08 December 2011
Abstract: Background: Hypoxia leads to changes in tumor cell metabolism such as increased glycolysis. In this study, we examined the spatial distribution of the glycolysis and hypoxia related markers ...
|
Tineke W.H. Meijer,
Olga C.J. Schuurbiers,
Johannes H.A.M. Kaanders,
Monika G. Looijen-Salamon,
Lioe-Fee de Geus-Oei,
Ad F.T.M. Verhagen,
Jasper Lok,
Henricus F.M. van der Heijden,
Saskia E. Rademakers,
Paul N. Span,
Johan Bussink
et al.
|
316-323
|
|
|
|
CHD5, a tumor suppressor that is epigenetically silenced in lung cancer
20 December 2011
Abstract: Chromodomain helicase DNA binding protein 5 (CHD5) is a potent tumor suppressor that serves as a master regulator of a tumor-suppressive network. Examination of the role played by CHD5 in a ...
|
Rui Zhao,
Qitao Yan,
Jingye Lv,
Haili Huang,
Wenling Zheng,
Bao Zhang,
Wenli Ma
et al.
|
324-331
|
|
|
|
Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood
19 December 2011
Abstract: Epidermal growth factor receptor (EGFR) is implicated in tumor development and is highly expressed in many human tumors. EGFR overexpression has been observed in both premalignant lesions an...
|
Sally Maramotti,
Massimiliano Paci,
Francesca Miccichè,
Alessia Ciarrocchi,
Alberto Cavazza,
Maida De Bortoli,
Elena Vaghi,
Debora Formisano,
Laura Canovi,
Giorgio Sgarbi,
Italia Bongarzone
et al.
|
332-338
|
|
| Imaging |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Small-cell carcinoma of the lung detected by CT screening: Stage distribution and curability
22 December 2011
Abstract: Background: Prognosis is incompletely known for small-cell lung carcinoma (SCLC) detected by CT screening of at-risk subjects. Methods: A multinational study of baseline and annual repeat CT...
|
John H.M. Austin,
Rowena Yip,
Belinda M. D'Souza,
David F. Yankelevitz,
Claudia I. Henschke,
for the International Early Lung Cancer Action Program Investigators
et al.
|
339-343
|
|
|
|
The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases
29 December 2011
Abstract: To evaluate FDG PET-CT in the detection of unexpected pre-malignancy or second malignancy at the initial staging of patients with histologically proven non-small cell lung cancer (NSCLC) and...
|
Michael Lin,
Chaitanya Ambati
|
344-349
|
|
|
|
Challenges scoring radiation pneumonitis in patients irradiated for lung cancer
09 January 2012
Abstract: Background and purpose: To quantify uncertainties in scoring radiation pneumonitis. Materials and methods: Records of 434 patients irradiated for lung cancer from 2000 to 2010 were retrospec...
|
Eda Yirmibesoglu,
Daniel S. Higginson,
Merdan Fayda,
M. Patricia Rivera,
Jan Halle,
Julian Rosenman,
Liyi Xie,
Lawrence B. Marks
et al.
|
350-353
|
|
| Treatment |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
26 December 2011
Abstract: Background: Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of ho...
|
Bartomeu Massuti,
Manuel Cobo,
Carlos Camps,
Manuel Dómine,
Mariano Provencio,
Vicente Alberola,
Nuria Viñolas,
Rafael Rosell,
Miguel Tarón,
Vanesa Gutiérrez-Calderón,
Pilar Lardelli,
Vicente Alfaro,
Antonio Nieto,
Dolores Isla
et al.
|
354-361
|
|
|
|
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
16 January 2012
Abstract: Purpose: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese p...
|
Seiji Niho,
Hideo Kunitoh,
Hiroshi Nokihara,
Takeshi Horai,
Yukito Ichinose,
Toyoaki Hida,
Nobuyuki Yamamoto,
Masaaki Kawahara,
Tetsu Shinkai,
Kazuhiko Nakagawa,
Kaoru Matsui,
Shunichi Negoro,
Akira Yokoyama,
Shinzoh Kudoh,
Katsuyuki Kiura,
Kiyoshi Mori,
Hiroaki Okamoto,
Hiroshi Sakai,
Koji Takeda,
Soichiro Yokota,
Nagahiro Saijo,
Masahiro Fukuoka,
JO19907 Study Group
et al.
|
362-367
|
|
|
|
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer
22 December 2011
Abstract: Background: The standard regimen in elderly patients with non-small-cell lung cancer (NSCLC) is still uncertain. Gemcitabine is one of the most widely used drugs for the treatment of NSCLC, ...
|
Jin Ho Baek,
Hawk Kim,
Jong-Joon Ahn,
Yangjin Jegal,
Kwang Won Seo,
Seung Won Ra,
Chang Ryul Park,
Jong Pil Jung,
Jeong Won Kim,
Yong Jik Lee,
Hee Jeong Cha,
Woon Jung Kwon,
Young Ju Noh,
Sukjoong Oh,
Jae-Hoo Park,
Young Joo Min
et al.
|
368-372
|
|
|
|
MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC
12 January 2012
Abstract: Introduction: The clinical benefit and safety profile associated with first-line bevacizumab with doublet chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCL...
|
Eric Dansin,
Saverio Cinieri,
Pilar Garrido,
Frank Griesinger,
Dolores Isla,
Manfred Koehler,
Martin Kohlhaeufl
et al.
|
373-379
|
|
|
|
A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer
09 January 2012
Abstract: Objective: The published data on the curative effects of comparing the once weekly paclitaxel-based chemotherapies (W-paclitaxel) with the standard every 3 weeks paclitaxel-based chemotherap...
|
Guanghui Gao,
Haiqing Chu,
Lan Zhao,
Tao Gui,
Qinghua Xu,
Jianping Shi
et al.
|
380-386
|
|
|
|
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
20 December 2011
Abstract: Background: We analyzed the patterns of treatment and clinical outcomes of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC) in the modern chemotherapy era. ...
|
Jin Hyun Park,
Yu Jung Kim,
Jeong-Ok Lee,
Keun-Wook Lee,
Jee Hyun Kim,
Soo-Mee Bang,
Jin-Haeng Chung,
Jae Sung Kim,
Jong Seok Lee
et al.
|
387-392
|
|
|
|
Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
26 December 2011
Abstract: Introduction: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant...
|
Thierry Jahan,
Lin Gu,
Robert Kratzke,
Arkadiusz Dudek,
Gregory A. Otterson,
Xiaofei Wang,
Mark Green,
Everett E. Vokes,
Hedy Lee Kindler
et al.
|
393-396
|
|
|
|
Estimation of renal function in lung cancer patients
19 December 2011
Abstract: Introduction: In lung cancer patients treated with chemotherapy, renal function is an important parameter to be monitored. Since measurement of renal function with either isotope or creatini...
|
Katja Trobec,
Lea Knez,
Pika Meško Brguljan,
Tanja Cufer,
Mitja Lainščak
et al.
|
397-402
|
|
| Clinical correlates |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma
02 December 2011
Abstract: Background: To characterize the clinicopathologic features of ALK-rearranged lung cancer, and suggest a molecular test protocol for lung adenocarcinoma in the small biopsy specimen. Methods:...
|
Jin Ho Paik,
Chang-Min Choi,
Hyojin Kim,
Se Jin Jang,
Gheeyoung Choe,
Dong Kwan Kim,
Hwa Jung Kim,
Hoil Yoon,
Choon-Taek Lee,
Sanghoon Jheon,
Ji-Young Choe,
Jin-Haeng Chung
et al.
|
403-409
|
|
|
|
Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
24 January 2012
Abstract: Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N=1590) from E1594, a 4-arm platin...
|
H.A. Wakelee,
S.E. Dahlberg,
J.R. Brahmer,
J.H. Schiller,
M.C. Perry,
C.J. Langer,
A.B. Sandler,
C.P. Belani,
D.H. Johnson,
Eastern Cooperative Oncology Group
et al.
|
410-415
|
|
|
|
FATS expression is associated with cisplatin sensitivity in non small cell lung cancer
05 December 2011
Abstract: Background: Although the survival benefit of cisplatin-based adjuvant chemotherapy has been proven for patients with non small cell lung cancer (NSCLC), the resistance to cisplatin and its d...
|
Yin Tian,
Jun Zhang,
Shuangshuang Yan,
Li Qiu,
Zheng Li
et al.
|
416-422
|
|
|
|
Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung
08 December 2011
Abstract: Tumor budding is morphologically defined as infiltration by small clusters of cancer cells. While the biological properties of budding cells in adenocarcinoma (decreased expression of adhesi...
|
Tetsuhiko Taira,
Genichiro Ishii,
Kanji Nagai,
Kiyotaka Yoh,
Yusuke Takahashi,
Yuki Matsumura,
Motohiro Kojima,
Hironobu Ohmatsu,
Koichi Goto,
Seiji Niho,
Hiroshi Takashima,
Hiromasa Inoue,
Yuichiro Ohe,
Atsushi Ochiai
et al.
|
423-430
|
|
|
|
Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma
11 January 2012
Abstract: Background: The overexpression of receptor tyrosine kinase EphA2 has been reported in various cancers. In non-small cell lung cancer (NSCLC), a positive correlation has been reported between...
|
Masashi Ishikawa,
Ryo Miyahara,
Makoto Sonobe,
Marika Horiuchi,
Toshi Mennju,
Ei Nakayama,
Masashi Kobayashi,
Ryutaro Kikuchi,
Jiro Kitamura,
Naoto Imamura,
Cheng-Long Huang,
Hiroshi Date
et al.
|
431-438
|
|
|
|
Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer
02 February 2012
Abstract: Introduction: To investigate whether decrease in the serum levels of pro-gastrin releasing peptide (ProGRP) and neuron-specific enolase (NSE) were correlated with the radiological response i...
|
Akira Ono,
Tateaki Naito,
Ichiro Ito,
Reiko Watanabe,
Takehito Shukuya,
Hirotsugu Kenmotsu,
Asuka Tsuya,
Yukiko Nakamura,
Haruyasu Murakami,
Kyoichi Kaira,
Toshiaki Takahashi,
Toru Kameya,
Takashi Nakajima,
Masahiro Endo,
Nobuyuki Yamamoto
et al.
|
439-444
|
|
|
|
Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas
02 February 2012
Abstract: Within the concert of immune reactions against tumour cells cytotoxic and regulatory T-cells are of utmost importance. Several studies revealed contradictory results on this issue. We theref...
|
Gian Kayser,
Luzie Schulte-Uentrop,
Wulf Sienel,
Martin Werner,
Paul Fisch,
Bernward Passlick,
Axel zur Hausen,
Christian Stremmel
et al.
|
445-451
|
|
|
|
History of tuberculosis as an independent prognostic factor for lung cancer survival
09 January 2012
Abstract: Introduction: It is well known that pulmonary tuberculosis is associated with an increased risk of lung cancer. We investigated whether a history of pulmonary tuberculosis is an independent ...
|
Marlies E. Heuvers,
Joachim G.J.V. Aerts,
Joost P. Hegmans,
Joris D. Veltman,
André G. Uitterlinden,
Rikje Ruiter,
Eline M. Rodenburg,
Albert Hofman,
Marleen Bakker,
Henk C. Hoogsteden,
Bruno H. Stricker,
Rob J. van Klaveren
et al.
|
452-456
|
|
|
|
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
02 February 2012
Abstract: Background: Socioeconomic status can potentially affect prognosis of cancer patients. Our aim was to describe potential differences in demographic and clinical characteristics, treatment, an...
|
Massimo Di Maio,
Simona Signoriello,
Alessandro Morabito,
Antonio Rossi,
Paolo Maione,
FrancoVito Piantedosi,
Domenico Bilancia,
Silvio Cigolari,
Santi Barbera,
Vittorio Gebbia,
Bruno Daniele,
Sergio Federico Robbiati,
Alfonso Illiano,
Anna Ceribelli,
Francesco Carrozza,
Adolfo Favaretto,
Elena Piazza,
Maria Carmela Piccirillo,
Gennaro Daniele,
Pasqualina Giordano,
Raffaele Costanzo,
Claudia Sandomenico,
Gaetano Rocco,
Ciro Gallo,
Francesco Perrone,
Cesare Gridelli
et al.
|
457-464
|
|
| Outcomes |
| |
Article Title |
Author(s) |
Pages |
|
|
|
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
07 December 2011
Abstract: Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC...
|
Mark J.C. Nuijten,
Javier de Castro Carpeño,
Christos Chouaid,
Alain Vergnenègre,
Francesco Grossi,
Helge Bischoff,
David Heigener,
Stefan Walzer
et al.
|
465-471
|
|
|
|
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis
09 January 2012
Abstract: Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to compare costs a...
|
Ian Cromwell,
Kimberly van der Hoek,
Suzanne C. Malfair Taylor,
Barbara Melosky,
Stuart Peacock
et al.
|
472-477
|
|
|
|
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses
25 January 2012
Abstract: In anemic patients receiving myelosuppressive chemotherapy, erythropoiesis-stimulating agents (ESAs) raise hemoglobin levels and reduce transfusion requirements, but ESA-related safety conce...
|
Johan Vansteenkiste,
John Glaspy,
David Henry,
Heinz Ludwig,
Robert Pirker,
Dianne Tomita,
Helen Collins,
Jeffrey Crawford
et al.
|
478-485
|
|
| Case reports |
| |
Article Title |
Author(s) |
Pages |
|
|
|
An ectopic ACTH-producing small cell lung carcinoma associated with enhanced corticosteroid biosynthesis in the peritumoral areas of adrenal metastasis
17 January 2012
Abstract: A 60-year-old Japanese male presented with swelling of bilateral cervical lymph nodes was subsequently diagnosed as the late stage of primary small cell lung carcinoma (SCLC). He was then tr...
|
Hironori Satoh,
Ryoko Saito,
Shu Hisata,
Jun Shiihara,
Shinji Taniuchi,
Yasuhiro Nakamura,
Toshihiro Nukiwa,
Masahito Ebina,
Hironobu Sasano
et al.
|
486-490
|
|
|
|
Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer
09 March 2012
Abstract: According to many published clinical trials, both haematological and non-haematological toxicities resulting from pemetrexed were relatively mild and therefore this drug is considered to be ...
|
Ming-Shyan Huang,
Jong-Rung Tsai,
Mei-Chiou Shen,
Shah-Hwa Chou,
Chih-Jen Yang
et al.
|
491-492
|
|
|
|
Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung
15 March 2012
Abstract: In contrast to leukocytosis, paraneoplastic hypereosinophilia is uncommon in lung cancer. We present a patient with large-cell carcinoma of the lung, in which cancer cells generate large amo...
|
Verena Lammel,
Christina Stoeckle,
Barbara Padberg,
Roland Zweifel,
Dirk L. Kienle,
Walter H. Reinhart,
Hans-Uwe Simon
et al.
|
493-495
|
|
|
|
Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma
09 April 2012
Abstract: Choroidal metastasis is uncommon and usually identified in a relatively advanced cancer status. The median survival after diagnosing choroid metastasis in lung cancer patients was only 1.9mo...
|
Chun-Liang Lai,
Kuo-Sheng Fan,
Yen-Hsien Lee,
Hsing-Chun Chen,
Wen-Hsiung Fan
et al.
|
496-498
|
|
| Correspondence |
| |
Article Title |
Author(s) |
Pages |
|
|
|
3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world
16 April 2012
We wish to add some comments regarding the recent article written by Cromwell et al. entitled “Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A rea...
|
Ching-Chan Lin,
Te-Chun Hsia,
Chun-Ru Chien
|
499-500
|
|
